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Abstract
Background: Xp11.2 or TFE3 translocation renal cell carcinomas (RCC) and alveolar soft part sarcoma (ASPS) are
characterized by chromosome translocations involving the Xp11.2 breakpoint resulting in transcription factor TFE3
gene fusions. The most common translocations documented in TFE3 RCCs are t(X;1) (p11.2;q21) and t(X;17) (p11.2;q25)
which leads to fusion of TFE3 gene on Xp11.2 with PRCC or ASPL respectively. TFE3 immunohistochemistry (IHC) has
been inconsistent over time due to background staining problems in part related to fixation issues. Karyotyping to
detect TFE3 gene rearrangement requires typically unavailable fresh tissue. Reverse transcriptase-polymerase chain
reaction (RT-PCR) is generally very challenging due to degradation of RNA in archival material. The study objective was
to develop and validate a TFE3 break-apart fluorescence in situ hybridization (FISH) assay to confirm Xp11 translocation
RCCs and ASPS.
Methods: Representative sections of formalin-fixed paraffin-embedded tissue blocks were selected in 40 possible cases.
Approximately 60 tumor cells were analyzed in the targeted region. The validation of TFE3 FISH was done with 11
negative and two positive cases. Cut off for a positive result was validated as >7.15 % positive nuclei with any pattern
of break-apart signals. FISH evaluation was done blinded of the immunohistochemical or karyotype data.
Results: Three out of forty cases were positive for the TFE3 break-apart signals by FISH. The negative cases were
reported as clear cell RCC with papillary features (10), clear cell RCC with sarcomatoid areas (2), Papillary RCC with clear
cell areas (9), Chromophobe RCC (2), RCC, unclassified type (3) and renal medullary carcinoma (1). 3 of the negative cases
were consultation cases for renal tumor with unknown histology. Seven negative cases were soft tissue tumor suspicious
for ASPS.
Conclusion: Our study validates the utility of TFE3 break-apart FISH on formalin-fixed paraffin-embedded tissue sections
for diagnosis and confirmation of Xp11.2 translocation RCCs and ASPS.
Keywords: TFE3 FISH, Xp11.2 Translocation Renal Cell Carcinoma, Alveolar Soft Part Sarcoma
Background
Xp11.2 or TFE3 translocation renal cell carcinoma (RCC)
is one of the new entities added in the 2004 World Health
Organization (WHO) classification of renal tumors [1].
They are characterized by translocations involving the
TFE3 transcription factor located at Xp11.2 locus. The five
known gene fusion partners of TFE3 are papillary 1 renal
cell carcinoma (PRCC), alveolar soft part sarcoma locus
(ASPL), polypyrimidine tract-binding protein-associated
splicing factor (PSF), non-POU domain-containing
octamer-binding (NonO, p54nrb), and clathrin heavy
chain (CLTC) genes, situated on chromosome loci 1q21
[2–5], 17q25 [6–8], 1p34 [9], Xq12 [9], and 17q23 [10]
respectively. The t(X; 17) (p11.2; q25) or TFE3-ASPL
translocation in RCC and alveolar soft part sarcoma
(ASPS) contain the identical TFE3-ASPL fusion tran-
script; however, the t(X; 17) translocation is consistently
balanced (reciprocal) in the Xp11.2 translocation RCC and
* Correspondence: pradhand@upmc.edu
1Department of Pathology, University of Pittsburgh Medical Center, 200
Lothrop Street, Pittsburgh 15213PA, USA
Full list of author information is available at the end of the article
© 2015 Pradhan et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pradhan et al. Diagnostic Pathology  (2015) 10:179 
DOI 10.1186/s13000-015-0412-z
unbalanced in the ASPS [11]. In translocation RCC involv-
ing t(X; 10) (p11; q23) or t(X;3) (p11.2;q23), the participat-
ing gene which fuses to TFE3 remains unknown [12, 13].
Xp11.2 RCCs are classically recognized as pediatric
RCC affecting children and young adults [14–20]. These
tumors are considered aggressive with early age of onset
and variable morphologic features including clear cell or
eosinophilic morphology, and papillary or alveolar archi-
tecture [21]. This entity seems to be underdiagnosed
and misclassified as clear cell or papillary RCC in adults,
because of overlapping morphologic features. Definite
diagnosis in suspicious cases requires confirmation of
the presence of TFE3 protein by immunohistochemistry
(IHC) or TFE3 gene rearrangement by karyotyping or
reverse transcriptase-polymerase chain reaction (RT-
PCR) to detect chimeric TFE3 mRNA fusion transcripts.
TFE3 IHC, though less time consuming and relatively
less expensive, has been inconsistent over time due to
background staining problems [22]. Besides variable
fixation time, especially common in consultation cases,
gives variable results [23]. False positive may often be
seen due to titration problem. Karyotyping requires fresh
tissue which is generally not sent for cytogenetic analysis
of adult renal masses in most institutes. RT-PCR on
formalin-fixed, paraffin-embedded (FFPE) tissue is infre-
quently used as a diagnostic tool. It is also very challen-
ging as fresh tissue is rarely available and there is
degradation of RNA in the archival material. Moreover,
it may necessitate multiple PCRs to cover all the known
partners of TFE3.
ASPS is a rare soft tissue tumor which has ASPL-TFE3
gene fusion as a result of unbalanced translocation der
(17) t(X;17) (p11;q25) or rarely a balanced translocation
t(X;17) (p11;q25). The classical alveolar pattern sur-
rounded by fibrous septa and large round to oval tumor
cells is fairly non-specific requiring help from ancillary
studies [11].
As the morphology of both Xp11.2 RCCs and ASPS are
non-specific and there are a lot of technical difficulties
with the available ancillary tools – IHC limited by equivo-
cal results, karyotyping limited by availability of viable
tumor cells and RT-PCR limited by RNA quality, we tried
to validate and utilize TFE3 break-apart fluorescence in-
situ hybridization (FISH) assay in FFPE tissue to confirm
the diagnosis of an Xp11.2 RCC and ASPS. Eventually, we
find that a break-apart FISH assay is an excellent diagnos-
tic and confirmatory test in the evaluation of TFE3 gene
rearrangement in primary as well as metastatic Xp11.2
RCCs and other TFE3 tumors.
Methods
FFPE tissue blocks were serially sectioned at 4 μ inter-
vals. Hematoxylin and eosin (H&E) sections were used
to determine the area of the tissue to be targeted for
analysis. FISH slides were deparaffinized in xylene twice
for 10 min, dehydrated twice with 100 % ethanol and
then pretreated using the Vysis Paraffin Pretreatment Kit
(Abbott Molecular, Des Plaines, IL). Slides were digested
for 36 min in protease solution (0.5 mg/ml) at 37 °C.
TFE3 FISH was performed using a dual-color break
apart probe labeled in Texas Red and FITC (Abnova
Co., Taipei, Taiwan). The target slide was denatured in
70 % Formamide at 75 °C for 5 min and dehydrated in
70, 85, and 100 % ethanol. Slides were incubated with
probe overnight at 42 °C in a humidified chamber. Post-
hybridization washes were performed using 2 × SSC/
0.3 % Igepal at 73 °C for 2 min (Sigma, St. Louis, MO).
Slides were air-dried in the dark and counterstained with
4,6-diamidino-2-phenylindole (DAPI)/antifade (Abbott
Molecular). All slides were kept at 4 °C in the dark after
hybridization. Analysis was performed using a Leica
DM5500 B fluorescence microscope (Leica Microsys-
tems) and CytoVision Workstation (Applied Imaging,
Santa Clara, CA) equipped with Chroma Technology
83,000 filter set with single and dual band excitors for
Texas Red, Spectrum Green, and DAPI (uv 360 nm)
(Abbott Molecular). Only individual and well delineated
cells were scored. Overlapping cells were excluded from
the analysis. Approximately 60 tumor cell nuclei were
analyzed in the targeted region by each of the 2 experi-
enced technicians. The expected normal nuclei had 2 fu-
sion signals reflecting intact TFE3 alleles in a female
individual and 1 fusion signal reflecting an intact TFE3
allele in a male individual. The signal pattern 1 red 1
green 1 fusion (yellow) was the most common positive
pattern for a balanced TFE3 translocation in a female
individual, whereas the signal pattern 1 red 1 green was
the most typical positive pattern for a balanced TFE3
rearrangement in a male individual (Fig. 1). Unbalanced
translocations in a female individual yielded a 1 red 2
Fig. 1 TFE3 FISH image indicating TFE3 gene rearrangement with
widely separated red and green signals
Pradhan et al. Diagnostic Pathology  (2015) 10:179 Page 2 of 5
fusion pattern. To be scored as a break apart and to avoid
false positive, the signals had to be separated by >2 signal
diameters. To avoid false negative in a 4 μ section where
red or green signal may be out of the visible plane of
section, a minimum of 60 nuclei were evaluated per case.
To determine a cutoff for a positive result, 11 negative
and 2 positive cases were evaluated using statistical criteria.
Cut off for a positive result was calculated as >7.15 % posi-
tive nuclei with any pattern of break-apart signals when 60
nuclei were scored thoroughly. FISH evaluation was done
blinded of the IHC or karyotype data.
Results
A total of 40 cases were evaluated for a TFE3 gene re-
arrangement using a break-apart FISH which comprised
33 renal neoplasms and 7 soft tissue sarcomas suspicious
for Xp11.2 RCC and ASPS respectively. The evaluation
was done blinded of morphologic possibility, karyotype,
and TFE3 IHC results. Of the 40 cases, 3 cases were
positive for the TFE3 break-apart signals by FISH. On
retrospective analysis of these 3 cases, one was a 26-
year-old female with unilateral renal mass diagnosed
morphologically as chromophobe RCC arising in a cyst,
stage pT1b, positive for CD-10, E-cadherin, caveolin and
parvalbumin; focally positive for AE1/AE3, CAM5.2,
CK7, EMA, RCC antigen and colloidal iron; and negative
for carbonic anhydrase IX and BerEP4. This case was
later subjected to TFE3 IHC which was positive. The
cytogenetic analysis of this case revealed a novel trans-
location involving t(X;19) (p11.2;q13.1). The other was a
renal tumor consultation case in a 10-year-old male
child. The third positive case was a 39-year-old male
with 12.8 cm retroperitoneal mass diagnosed as pT2b
ASPS in 2002. He had a left upper lobe lung metastasis
in 2006 and a jejunal metastasis in 2014. This jejunal
metastasis revealed the TFE3 gene rearrangement when
subjected to break apart FISH. The negative cases were
reported as clear cell RCC with papillary features (10),
clear cell RCC with sarcomatoid areas (2), Papillary RCC
with clear cell areas (9), Chromophobe RCC (2), RCC,
unclassified type (3) and renal medullary carcinoma (1).
Three of the negative cases were consultation cases for
renal tumor with unknown histology. Seven negative
cases were soft tissue tumor suspicious for ASPS.
FISH evaluation of tissue used for validation purpose
showed break-apart signals in both positive cases, each
of TFE3 RCC and ASPS, but in none of the non-Xp11.2
RCCs and normal tissue.
Discussion
Xp11.2 translocation carcinoma is a recently recognized
entity in the 2004 WHO renal tumor classification [1]. It
is an uncommon tumor generally arising in children and
young adults but recently has been recognized in adults
as old as 58 years [24–36]. To date, 5 distinct reciprocal
gene fusion partners of the TFE3 gene located at Xp11.2
have been recognized in RCCs which include ASPL,
PRCC, PSF, NonO, and CLTC situated on chromosome
loci 17q25, 1q21, 1p34, Xq12, and 17q23 respectively
[2–10]. Another rare group of renal carcinomas showing
the translocation t(6; 11) (p21; q12) involving transcrip-
tion factor EB (TFEB) has also been reported [37, 38].
TFE3 and TFEB belong to the microphthalmia transcrip-
tion factor (MiTF) subfamily, which also includes MiTF
and transcription factor EC. Argani and Ladanyi have
proposed regrouping these neoplasms into the category
of MiTF/TFE family translocation carcinomas [21].
The most characteristic morphologic pattern of the
Xp11.2 translocation RCC is that of an epithelioid neo-
plasm with predominance of clear cells, papillary archi-
tecture and psammoma bodies. TFE3 translocation
RCCs regularly express CD10 and the RCC marker, and
most express the renal transcription factors PAX2 and
PAX8. In contrast, they are less immunoreactive for epi-
thelial markers such as cytokeratins and EMA [29]. Few
of them are reactive for melanocytic markers such as
Melan A and HMB45. Infrequently, they may also
express papain-like cystein protease cathepsin K. These
tumors show characteristically strong nuclear TFE3
immunostaining [39, 40].
ASPS is a rare soft tissue tumor that harbors the
ASPL-TFE3 gene fusion. These tumors are most often
seen in the deep soft tissues of the extremities. Classic-
ally, the tumors show the distinctive alveolar growth pat-
tern and strong nuclear immunostaining for TFE3 [41].
The morphologic differential diagnosis of Xp11.2
translocation RCC is quite broad. The most common
renal neoplasms that mimic TFE3 RCCs are those with
clear cells and papillary architecture. These include clear
cell RCC with focal papillary/pseudopapillary areas, pap-
illary RCC with focal clear cell areas and clear cell
papillary RCC. Diffuse carbonic Anhydrase-IX (CA-IX)
immune-labeling of clear cell RCC and cytokeratin 7 la-
beling of papillary RCC may help differentiate the TFE3
RCCs, which will show strong nuclear immunoreactivity
for TFE3 IHC. Clear cell papillary RCC typically shows a
branching tubular architecture, has apically aligned nu-
clei with subnuclear clearing, and reveals a low nuclear
grade. Other neoplasms that may be confused with
Xp11.2 translocation RCC include chromophobe RCC.
Diffuse CD117 labeling favors chromophobe RCC over
Xp11 translocation RCC.
Besides Xp11 translocation RCC and ASPS, perivascu-
lar epithelioid cell tumors (PEComas) have also shown
immunoreactivity for TFE3. Folpe et al. showed that five
of 17 PEComas were TFE3 positive [42]. Recently, a case
of PEComa with PSF-TFE3 gene fusion proven by FISH
and RT-PCR has been reported [43]. Interestingly,
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Argani et al. reported a distinctive type of renal cancer
with overlapping features of PEComa, Xp11 transloca-
tion carcinoma, and melanoma [44].
The diagnosis of Xp11 translocation carcinoma can be
problematic in cases of unusual clinical or morphologic
presentation or technical difficulty with TFE3 IHC stain-
ing. TFE3 IHC may be inconsistent due to many reasons
like variation in staining in different lot because of poly-
clonal antibody, fixation dependence of the antibody and
the subjectivity in interpretation of the TFE3 IHC. As
such, cytogenetic examination of fresh tissue remains
the gold standard. When fresh tissue is unavailable, FISH
and/or RT-PCR can be performed on FFPE tissues.
However, RT-PCR of archival tissue is difficult due to
degradation of RNA, insufficient extraction efficiency
and difficulty with the availability of adequate material
in small biopsy samples. In addition, Xp11.2 transloca-
tion RCC has at least five known fusion partners with
TFE3 making RT-PCR more time consuming and labor
intensive. Potential unknown translocation(s) involving
the TFE3 gene may yield false negative results. FISH on
the other hand represents a cost and time-efficient
method that uses FFPE tissue. Aulmann et al. has
reported the feasibility of detecting the ASPS-TFE3 gene
fusion in ASPS with both split and fusion probes [45].
Their paper is the first development of a FISH assay for
the detection of TFE3 gene translocation in paraffin-
embedded tissues. The advantage of the break apart
probe type FISH assay is that though the fusion partner
with TFE3 is not identified, but potentially all transloca-
tions involving TFE3 can be detected. Because all the
probes target the X chromosome, the patient’s sex is
important for FISH interpretation. The male patient
should have one pair of signals (1 X chromosome) and
the female patient should have two pairs of signals (2 X
chromosomes).
Conclusion
In this study, we validated a TFE3 break apart FISH
assay to aid as a relatively rapid test for detecting Xp11.2
translocation in cases of TFE3 RCC and ASPS. This
FISH assay can be utilized as an adjunct to morphology
and immunohistochemistry to diagnose TFE3-associated
carcinomas and other neoplasms.
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